You are here: Industry Insights > KB

News List

Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field? Kevin
April 15, 2025
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.
A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
With Anlotinib Sold over RMB4 Billion in 2020, Which will be the Next Blockbuster of Sino Biopharmaceutical? PharmaSources/Caicai
May 31, 2021
Sino Biopharmaceutical has recently released its 2020 annual results, with total revenue of RMB23.647 billion, down 2.4% year on year, net profit attributable to the parent of RMB2.771 billion, up 0.3% year on year
A Better Anti-Influenza Solution: Roche’s Blockbuster New Drug Applied for Marketing in China PharmaSources/Xiaoyaowan
June 24, 2020
According to the website of the CDE on June 10, the marketing applications of Roche for its new drug Baloxavir Marboxil Tablets in China have been accepted by the CDE.
Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors PR Newswire
March 26, 2025
Kelun-Biotech's RDC drug SKB107 got clinical trial approval for bone metastases. It's jointly developed, with expected advantages.
ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China PR Newswire
March 24, 2025
ArkBio completed AK0901's Phase III study for ADHD. It's a novel drug with good results, set to offer new options for Chinese ADHD kids.
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb). PR Newswire
January 11, 2025
Kelun - Biotech & Harbour BioMed Jan 11, 2025 focus on exclusive license of SKB378/HBM9378, a TSLP mAb, to Windward Bio
AXA and HKBN Deepen Collaboration with Launch of "HKBN SmartTraveller Plus" PR Newswire
December 11, 2024
AXA Hong Kong and Macau (AXA) and Hong Kong Broadband Network Limited (HKBN) have taken their collaboration another step forward by introducing "HKBN SmartTraveller Plus"
AskBio, Touchlight Restructure Former JV, Touchlight AAV contractpharma
February 08, 2022
Both parties benefit from co-exclusive rights to independently supply the Adeno-Associated Virus (AAV) market with doggybone DNA.
Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report prnasia
January 10, 2022
Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch? report...